Shenzhen Qiaoyantang Biotechnology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Shenzhen Qiaoyantang Biotechnology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include CHOYTONG. The owner is based in Shenzhen.

902, No. 51, Songzaiyuan Second Dist.,

Daling Community, Longhua Dist.,

Shenzhen 518000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Shenzhen Qiaoyantang Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Shenzhen Qiaoyantang Biotechnology Co., Ltd. have?

Shenzhen Qiaoyantang Biotechnology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.

What trademark classes does Shenzhen Qiaoyantang Biotechnology Co., Ltd. file in?

Shenzhen Qiaoyantang Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Shenzhen Qiaoyantang Biotechnology Co., Ltd.'s most well-known trademarks?

Shenzhen Qiaoyantang Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as CHOYTONG. These are among 1 currently registered trademark in the portfolio.

What is Shenzhen Qiaoyantang Biotechnology Co., Ltd.'s trademark registration success rate?

Shenzhen Qiaoyantang Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.